Navigation Links
ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board

HALIFAX, Sept. 27 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT) finalizes an important step in its progress with the last appointment to its scientific advisory board (SAB), international oncology expert, Dr. Neil Berinstein.

Dr. Berinstein is the Global Head of the Cancer Vaccine Program at sanofi pasteur, and a professor at the University of Toronto's Department of Medicine. He has a long track record in fundamental research and has a significant publication record in the area of normal and malignant B cell biology, including articles, abstracts and book chapters on immunotherapeutic approaches for cancer including cancer vaccines. He was recently appointed vice-president of the Sabin Institute Cancer vaccine consortium. Dr. Berinstein received an MD from the University of Manitoba, and completed training programs at the University of Toronto in Internal Medicine and Medical Oncology. Following this, he spent four years as a post-doctoral fellow in Dr. Ron Levy's Lab at Stanford University working in the area of immunotherapy for cancer.

"IVT has very promising science," remarked Dr. Berinstein. "Their work is particularly interesting to me, and my commitment to new immunotherapeutic approaches for patients with cancer. "

ImmunoVaccine Technologies Inc. has been actively recruiting members to its SAB in preparation for its Phase I clinical trials, and sees this final appointment as a major stepping stone to that goal.

"This final appointment is one of the last steps before our Phase I clinical trials," said Dr. Martin Kast, chair of the scientific advisory board. "Dr. Berinstein's experience and insight are reflective of the quality of professionals that our exciting projects have attracted," continued Kast.

"Dr. Berinstein is a valuable addition to the team, and represents a pivotal point in our ongoing plan to introduce our patented vaccine platform," commented Dr. Randal Chase, president and CEO of IVT.

ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases.

SOURCE ImmunoVaccine Technologies Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
Breaking Biology Technology:
(Date:10/4/2017)... a global clinical research organization (CRO), announces the launch of Shadow, ... 2017. Shadow is designed to assist medical writers and biometrics teams ... European Medicines Agency (EMA) in meeting the requirements for de-identifying clinical ... ... Tom ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
Breaking Biology News(10 mins):